US 11,807,619 B2
Para acyl substituted diazacyclohexene derivatives
Bishwajit Nag, Union City, CA (US); Ananda Sen, Castro Valley, CA (US); Nitish Nag, Union City, CA (US); Arjun Sanyal, Castro Valley, CA (US); and Srinivasan Narasimhan, Chennai (IN)
Filed by Renovel Innovations, Inc, Fremont, CA (US)
Filed on Oct. 12, 2021, as Appl. No. 17/499,728.
Claims priority of provisional application 63/141,889, filed on Jan. 26, 2021.
Prior Publication US 2022/0235004 A1, Jul. 28, 2022
Int. Cl. C07D 339/08 (2006.01); C07D 409/12 (2006.01); C07D 211/60 (2006.01); C07D 401/12 (2006.01)
CPC C07D 339/08 (2013.01) [C07D 211/60 (2013.01); C07D 401/12 (2013.01); C07D 409/12 (2013.01)] 7 Claims
 
1. The pharmacologically active compound described as follows:
Compound 1 (also named RNV-170), C24H24N2O6, having the chemical name of: 4-[3-Methoxy-4-(3-phenyl-acryloyloxy)-phenyl]-6-Methyl 2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester, and having the following structure:

OG Complex Work Unit Chemistry
and pharmaceutically acceptable salts, thereof.